Cardiff Oncology Past Earnings Performance
Past criteria checks 0/6
Cardiff Oncology's earnings have been declining at an average annual rate of -21.5%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 9.7% per year.
Key information
-21.5%
Earnings growth rate
49.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 9.7% |
Return on equity | -59.4% |
Net Margin | -8,496.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24Revenue & Expenses BreakdownBeta
How Cardiff Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -41 | 13 | 0 |
30 Sep 23 | 0 | -41 | 13 | 0 |
30 Jun 23 | 0 | -40 | 14 | 0 |
31 Mar 23 | 0 | -39 | 12 | 0 |
31 Dec 22 | 0 | -39 | 13 | 0 |
30 Sep 22 | 0 | -39 | 14 | 0 |
30 Jun 22 | 0 | -38 | 14 | 0 |
31 Mar 22 | 0 | -34 | 14 | 0 |
31 Dec 21 | 0 | -28 | 12 | 0 |
30 Sep 21 | 0 | -25 | 11 | 0 |
30 Jun 21 | 0 | -23 | 10 | 0 |
31 Mar 21 | 0 | -24 | 9 | 0 |
31 Dec 20 | 0 | -23 | 8 | 0 |
30 Sep 20 | 0 | -20 | 6 | 0 |
30 Jun 20 | 0 | -20 | 6 | 0 |
31 Mar 20 | 0 | -17 | 6 | 0 |
31 Dec 19 | 0 | -17 | 6 | 0 |
30 Sep 19 | 0 | -17 | 6 | 0 |
30 Jun 19 | 0 | -16 | 6 | 0 |
31 Mar 19 | 0 | -19 | 7 | 0 |
31 Dec 18 | 0 | -19 | 8 | 0 |
30 Sep 18 | 0 | -18 | 8 | 0 |
30 Jun 18 | 1 | -18 | 11 | 0 |
31 Mar 18 | 1 | -20 | 11 | 0 |
31 Dec 17 | 1 | -25 | 12 | 0 |
30 Sep 17 | 0 | -31 | 14 | 0 |
30 Jun 17 | 0 | -37 | 16 | 0 |
31 Mar 17 | 0 | -39 | 19 | 0 |
31 Dec 16 | 0 | -39 | 22 | 0 |
30 Sep 16 | 0 | -38 | 22 | 0 |
30 Jun 16 | 0 | -31 | 21 | 0 |
31 Mar 16 | 0 | -31 | 19 | 0 |
31 Dec 15 | 0 | -27 | 14 | 0 |
30 Sep 15 | 0 | -25 | 14 | 0 |
30 Jun 15 | 0 | -27 | 12 | 0 |
31 Mar 15 | 0 | -18 | 10 | 0 |
31 Dec 14 | 0 | -14 | 9 | 0 |
30 Sep 14 | 0 | -11 | 7 | 0 |
30 Jun 14 | 0 | -10 | 8 | 0 |
31 Mar 14 | 0 | -14 | 7 | 0 |
31 Dec 13 | 0 | -12 | 7 | 0 |
30 Sep 13 | 0 | -17 | 6 | 0 |
30 Jun 13 | 1 | -13 | 5 | 0 |
31 Mar 13 | 1 | -12 | 4 | 0 |
Quality Earnings: CRDF is currently unprofitable.
Growing Profit Margin: CRDF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRDF is unprofitable, and losses have increased over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare CRDF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRDF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CRDF has a negative Return on Equity (-59.42%), as it is currently unprofitable.